Standardization of VTE incidence rates of the study population of relatives according to sex and age, considering the general population as reference
| Proband characteristics and relatives’ sex and age, y . | Incidence rate, general population* . | Study population (patient-years) . | Observed VTE . | Expected VTE . |
|---|---|---|---|---|
| Homozygous and VTE – | ||||
| Men | ||||
| 20-24 | 0.13 | 392 | 0 | 0.05 |
| 25-39 | 0.16 | 809 | 0 | 0.13 |
| 40-54 | 0.65 | 494 | 1 | 0.32 |
| 55-69 | 1.80 | 222 | 0 | 0.40 |
| 70+ | 4.71 | 22 | 0 | 0.10 |
| Women | ||||
| 15-24 | 0.36 | 490 | 0 | 0.18 |
| 25-39 | 0.40 | 1112 | 2 | 0.44 |
| 40-54 | 0.79 | 801 | 0 | 0.63 |
| 55-69 | 1.56 | 295 | 0 | 0.46 |
| 70+ | 4.67 | 33 | 0 | 0.15 |
| Overall | 3 | 2.86 | ||
| Homozygous and VTE + | ||||
| Men | ||||
| 20-24 | 0.13 | 502 | 1 | 0.07 |
| 25-39 | 0.16 | 1069 | 0 | 0.17 |
| 40-54 | 0.65 | 661 | 0 | 0.43 |
| 55-69 | 1.80 | 227 | 2 | 0.41 |
| 70+ | 4.71 | 46 | 0 | 0.22 |
| Women | ||||
| 20-24 | 0.36 | 734 | 1 | 0.26 |
| 25-39 | 0.40 | 1611 | 1 | 0.64 |
| 40-54 | 0.79 | 1014 | 1 | 0.80 |
| 55-69 | 1.56 | 376 | 0 | 0.59 |
| 70+ | 4.67 | 61 | 0 | 0.28 |
| Overall | 6 | 3.87 | ||
| Heterozygous and VTE – | ||||
| Men | ||||
| 20-24 | 0.13 | 221 | 0 | 0.03 |
| 25-39 | 0.16 | 540 | 0 | 0.09 |
| 40-54 | 0.65 | 344 | 1 | 0.22 |
| 55-69 | 1.80 | 167 | 2 | 0.30 |
| 70+ | 4.71 | 25 | 0 | 0.12 |
| Women | ||||
| 20-24 | 0.36 | 310 | 0 | 0.11 |
| 25-39 | 0.40 | 722 | 0 | 0.29 |
| 40-54 | 0.79 | 435 | 1 | 0.34 |
| 55-69 | 1.56 | 171 | 0 | 0.27 |
| 70+ | 4.67 | 9 | 0 | 0.04 |
| Overall | 4 | 1.81 | ||
| Heterozygous and VTE + | ||||
| Men | ||||
| 20-24 | 0.13 | 420 | 0 | 0.05 |
| 25-39 | 0.16 | 930 | 1 | 0.15 |
| 40-54 | 0.65 | 498 | 0 | 0.32 |
| 55-69 | 1.80 | 203 | 1 | 0.37 |
| 70+ | 4.71 | 37 | 0 | 0.17 |
| Women | ||||
| 20-24 | 0.36 | 538 | 2 | 0.19 |
| 25-39 | 0.40 | 1225 | 5 | 0.49 |
| 40-54 | 0.79 | 728 | 1 | 0.58 |
| 55-69 | 1.56 | 286 | 3 | 0.45 |
| 70+ | 4.67 | 57 | 1 | 0.27 |
| Overall | 14 | 3.04 |
| Proband characteristics and relatives’ sex and age, y . | Incidence rate, general population* . | Study population (patient-years) . | Observed VTE . | Expected VTE . |
|---|---|---|---|---|
| Homozygous and VTE – | ||||
| Men | ||||
| 20-24 | 0.13 | 392 | 0 | 0.05 |
| 25-39 | 0.16 | 809 | 0 | 0.13 |
| 40-54 | 0.65 | 494 | 1 | 0.32 |
| 55-69 | 1.80 | 222 | 0 | 0.40 |
| 70+ | 4.71 | 22 | 0 | 0.10 |
| Women | ||||
| 15-24 | 0.36 | 490 | 0 | 0.18 |
| 25-39 | 0.40 | 1112 | 2 | 0.44 |
| 40-54 | 0.79 | 801 | 0 | 0.63 |
| 55-69 | 1.56 | 295 | 0 | 0.46 |
| 70+ | 4.67 | 33 | 0 | 0.15 |
| Overall | 3 | 2.86 | ||
| Homozygous and VTE + | ||||
| Men | ||||
| 20-24 | 0.13 | 502 | 1 | 0.07 |
| 25-39 | 0.16 | 1069 | 0 | 0.17 |
| 40-54 | 0.65 | 661 | 0 | 0.43 |
| 55-69 | 1.80 | 227 | 2 | 0.41 |
| 70+ | 4.71 | 46 | 0 | 0.22 |
| Women | ||||
| 20-24 | 0.36 | 734 | 1 | 0.26 |
| 25-39 | 0.40 | 1611 | 1 | 0.64 |
| 40-54 | 0.79 | 1014 | 1 | 0.80 |
| 55-69 | 1.56 | 376 | 0 | 0.59 |
| 70+ | 4.67 | 61 | 0 | 0.28 |
| Overall | 6 | 3.87 | ||
| Heterozygous and VTE – | ||||
| Men | ||||
| 20-24 | 0.13 | 221 | 0 | 0.03 |
| 25-39 | 0.16 | 540 | 0 | 0.09 |
| 40-54 | 0.65 | 344 | 1 | 0.22 |
| 55-69 | 1.80 | 167 | 2 | 0.30 |
| 70+ | 4.71 | 25 | 0 | 0.12 |
| Women | ||||
| 20-24 | 0.36 | 310 | 0 | 0.11 |
| 25-39 | 0.40 | 722 | 0 | 0.29 |
| 40-54 | 0.79 | 435 | 1 | 0.34 |
| 55-69 | 1.56 | 171 | 0 | 0.27 |
| 70+ | 4.67 | 9 | 0 | 0.04 |
| Overall | 4 | 1.81 | ||
| Heterozygous and VTE + | ||||
| Men | ||||
| 20-24 | 0.13 | 420 | 0 | 0.05 |
| 25-39 | 0.16 | 930 | 1 | 0.15 |
| 40-54 | 0.65 | 498 | 0 | 0.32 |
| 55-69 | 1.80 | 203 | 1 | 0.37 |
| 70+ | 4.71 | 37 | 0 | 0.17 |
| Women | ||||
| 20-24 | 0.36 | 538 | 2 | 0.19 |
| 25-39 | 0.40 | 1225 | 5 | 0.49 |
| 40-54 | 0.79 | 728 | 1 | 0.58 |
| 55-69 | 1.56 | 286 | 3 | 0.45 |
| 70+ | 4.67 | 57 | 1 | 0.27 |
| Overall | 14 | 3.04 |
Per 1000 patient-years. Data obtained from Naess et al.17